Previous 10 | Next 10 |
2024-05-03 12:54:44 ET More on Axsome Therapeutics Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges Axsome Therapeutics, Inc. (AXSM) Q4 2023 Earnings Call Transcript Axsome Therapeutics stock rises on upgrade to Overweight at Morgan Sta...
2024-05-01 10:45:03 ET XPeng Inc (XPEV) XPEV is trading UP for the last 5 days, and it at trading at $8.16 with volume of 3,591,457 and a one day change of $0.03 (0.31%). XPeng Inc has a 52-week low of 6.55 and a 52-week high of $23.62. The business's 50-day moving average price is ...
NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today is joining the global community of mental health advocates, including Ment...
2024-04-29 10:08:15 ET More on Axsome Therapeutics Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges Axsome Therapeutics, Inc. (AXSM) Q4 2023 Earnings Call Transcript Baird starts Axsome at outperform, cites upcoming data Axsome ...
2024-04-25 18:28:44 ET Summary Neurocrine Biosciences, Inc. achieved positive results achieved from phase 2 SAVITRI study using NBI-1065845 for the treatment of patients with Major Depressive Disorder. NBI-1065845 may offer some advantages over currently approved MDD therapies, su...
2024-04-24 11:59:30 ET More on Neurocrine Biosciences Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside Neurocrine Biosciences (NBIX) Q4 2023 Earnings Call Transcript Neurocrine succeeds in mid-stage trial for Takeda-partnered depression d...
2024-04-16 13:17:12 ET Summary Intra-Cellular Therapies, Inc. achieved positive results from Study 501, using lumateperone as an adjunctive therapy for the treatment of patients with MDD; Both primary and secondary endpoints achieved with statistical significance. The Major Depres...
AXS-05 in Alzheimer’s disease agitation data featured in oral plenary session New data for AXS-07 in migraine demonstrating efficacy in pooled analysis Presentations on cognitive and wake promoting effects of solriamfetol NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) --...
2024-04-10 10:40:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Markets appear to have...
2024-04-10 10:15:00 ET Exciting growth stocks are highly coveted, but some fly under the radar for various reasons. And this gives astute investors the opportunity to pounce before their shares rise significantly. Mid-cap biotechs Madrigal Pharmaceuticals (NASDAQ: MDGL) and Ax...
News, Short Squeeze, Breakout and More Instantly...
Axsome Therapeutics Inc. Company Name:
AXSM Stock Symbol:
NASDAQ Market:
Axsome Therapeutics Inc. Website:
PALM BEACH, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The fibromyalgia treatment market has witnessed positive growth trends over the past few years. There is higher disease awareness due to growth in diagnosis rates and growing awareness and concern for this se...
2024-07-15 07:15:00 ET Any stock can have an impressive run, especially when broader equities are experiencing a bull market. Significantly fewer stocks can perform well through good and not-so-good times and deliver excellent returns over long periods. These are precisely the sort of corpo...
NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it will report its financial results for the second quarter of ...